News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
TILT Biotherapeutics, a biotech company developing cancer immunotherapies, has announced that the first patient has been dosed in a phase 1 trial of the company’s oncolytic adenovirus TILT-123.
SiSaf has been granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (PRDD) by the US Food and Drug Administration (FDA) for its osteopetrosis treatment, SIS-101-ADO.
Boston-based radiopharmaceutical company Ratio Therapeutics has opened a new 19,000 square foot headquarters and R&D facility.
Acesion Pharma has announced positive data from pre-clinical studies with AP31969, developed for chronic oral maintenance treatment to prevent atrial fibrillation (AF) recurrence.